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Abstract
Purpose PGG–PTX is a water-soluble formulation of
paclitaxel (PTX), made by conjugating PTX to poly(L-c-
glutamylglutamine) acid (PGG) via ester bonds, that
spontaneously forms a nanoparticle in aqueous environ-
ments. The purpose of this study was to compare the
pharmacokinetics and tissue distribution of PTX following
injection of either free PTX or PGG–PTX in mice.
Experimental design Both [
3H]PTX and PGG–[
3H]PTX
were administered as an IV bolus injection to mice bearing
SC NCI-H460 lung cancer xenografts at a dose of 40-mg
PTX equivalents/kg. Plasma, tumor, major organs, urine,
and feces were collected at intervals out to 340 h. Total
taxanes, taxane extractable into ethyl acetate, and native
PTX were quantiﬁed by liquid scintillation counting and
HPLC.
Results Conjugation of PTX to the PGG polymer
increased plasma and tumor Cmax, prolonged plasma half-
life and the period of accumulation in tumor, and reduced
washout from tumor. In plasma injection of PGG–PTX
increased total taxane AUC0–340 by 23-fold above that
attained with PTX. In tumors, it increased the total taxane
by a factor of 7.7, extractable taxane by 5.7, and native
PTX by a factor of 3.5-fold. Conjugation delayed and
reduced total urinary and fecal excretion of total taxanes.
Conclusions Incorporation of PTX into the PGG–PTX
polymer signiﬁcantly prolonged the half-life of total tax-
anes, extractable taxane, and native PTX in both the plasma
and tumor compartments. This resulted in a large increase
in the amount of active PTX delivered to the tumor. PGG–
PTX is an attractive candidate for further development.
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Abbreviations
PGA Poly(L-glutamic acid)
PGG Poly(L-c-glutamylglutamine)
PGG–PTX 70 kDa PGA to which both additional
glutamine side chains and PTX have been
added
PTX Paclitaxel
Introduction
Paclitaxel (PTX) has signiﬁcant anti-tumor activity in
patients with ovarian, breast, head, and neck cancer, and
non-small-cell lung carcinomas as well as sarcomas [10,
22]. Since PTX has limited solubility in water, it is cur-
rently formulated in a solution containing 6-mg PTX/ml in
Cremophor EL and ethanol (50% v/v) that must be further
diluted before administration. Cremaphor EL is a phar-
macologically active compound and its use is associated
with acute hypersensitivity reactions [5, 14]. Numerous
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DOI 10.1007/s00280-009-1058-xattempts have been made to develop PTX formulations
with reduced systemic toxicity and an enhanced therapeutic
index using other vehicles. These attempts have included
the use of liposomes, microspheres, micelles, nanoparti-
cles, prodrugs, and polymer–drug conjugates [5, 9, 11, 24,
27]. The greatest success achieved to date has been with
paclitaxel protein-bound particles for injection (Abraxane)
which is now marketed for the treatment of breast cancer.
In a continuing attempt to further improve the tumor
targeting and efﬁcacy of PTX, PTX was covalently con-
jugated to poly-(L-glutamic acid) (PG–PTX) to produce
paclitaxel poliglumex which has been in clinical develop-
ment for some time. This conjugate is less toxic than PTX
and has been reported to have signiﬁcant antitumor activity
in a variety of preclinical models [3, 6, 10, 17, 26, 28].
Pharmacokinetic studies in mice and patients indicate that
PG–PTX has a much longer plasma residence time than
PTX, and only a small amount of free PTX is present in the
plasma after IV injection of PG–PTX (reviewed in [27]).
However, despite favorable phase II clinical trial results
[12, 21, 23], three randomized phase III trials in patients
with non-small cell lung cancer failed to demonstrate an
improvement in either progression-free or overall survival
[8, 16, 18].
Poly(L-c-glutamylglutamine) (PGG) is a novel type of
polymer consisting of a poly-glutamate in which an addi-
tional glutamine side chain has been added to each glut-
amyl monomer in the backbone as shown in Fig. 1. When
the additional glutamines are added to 70 kDa PGA, and
PTX is covalently conjugated via an ester linkage to 35%
(w/w), the PGG–PTX spontaneously forms a micellar
nanoparticle in aqueous solutions with a median diameter
of 20 nm as determined by dynamic light scattering. This
novel formulation has activity superior to that of Abraxane
in the B16 murine melanoma, NCI-H460 non-small cell
lung cancer, and 2008 ovarian cancer models. The goal of
the present study is to determine how conjugation of PTX
to the PGG polymer backbone alters the pharmacokinetics,
tissue distribution, and excretion of PTX in nu/nu mice
bearing NCI-H460 human lung cancer xenografts.
Materials and methods
Drugs
Paclitaxel (PTX) was obtained from Nublock, LLC. Vista,
CA. [
3H]PTX was purchased from Moravek Biochemicals,
Inc. (Brea, CA) and had a speciﬁc activity of 1 mCi/177 lg
PTX (or 56.50 mCi/mg PTX). Unlabeled PTX was dis-
solved in ethanol and mixed with a stock solution of
[
3H]PTX to yield [
3H]PTX with a speciﬁc activity of
9.98 lCi/mg. After evaporation of the ethanol, [
3H]PTX
was redissolved in Cremophor/alcohol (1:1 v/v) at a con-
centration of 30 mg/ml. This solution was further diluted
1:5 in 0.9% NaCl in water to produce a ﬁnal concentration
of 6.0 mg/ml prior to IV injection. PGG–[
3H]PTX was
synthesized by conjugating [
3H]PTX to 70 kDa poly(L-
glutamic acid) in which each glutamyl monomer was
substituted with an additional glutamine and then loaded to
35% w/w with PTX and [
3H]PTX to produce a ﬁnal spe-
ciﬁc activity of 9.98 lCi/mg equivalent PTX. Before
injection, the conjugate was dissolved in saline to an
equivalent PTX concentration of 6 mg/ml and ﬁltered
through a 0.22-lm sterile ﬁlter.
Animals
Female nu/nu mice (22–30 g) were obtained from Charles
River Laboratories and maintained in a pathogen-free
vivarium. All experiments involving animals were per-
formed in accordance with the guidelines of the institution’s
Animal Care and Use Committee. Mice were inoculated
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Fig. 1 Structure of PGG–PTX, a random ester conjugate of poly(L-c-
glutamylglutamine) and paclitaxel. The structure shown is illustrative
of a fragment of the molecule, but speciﬁc conjugation sites are not
implied. There are approximately ﬁve non-conjugated monomer
glutamylglutamine units per paclitaxel-conjugated monomer glutam-
ylglutamine unit
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6 NCI-H460 human lung cancer cells that
had been grown in tissue culture on each shoulder and hip.
At the point when the mean tumor volume for the entire
population had reached 400–500 mm
3, each mouse
received a single IV bolus injection of [
3H]PTX or PGG–
[
3H]PTX at a dose of 40 mg PTX equivalents/kg.
Sample collection and counting of total drug
radioactivity
Six mice were anesthetized at each of 0, 0.166, 0.5, 2, 4,
24, 48, 72, 144, 240, and 340 h after injection of either
[
3H]PTX or PGG–[
3H]PTX and at least 0.5 ml of whole
blood was drawn from the heart immediately prior to
killing and after induction of anesthesia with ketamine
100 mg/kg and xylacine 10 mg/kg. The blood was placed
in an Eppendorf tube containing 10 ll heparin 1,000 U/ml
and plasma was separated from formed elements by
centrifugation and frozen for later processing. Each of the
four tumors per mouse and a *100 mg sample from the
right lower lobe of the lung, right lobe of the liver, right
kidney, and skeletal muscle, and the entire spleen was
dissected free of surrounding tissue, blotted free of ﬂuid,
and weighed. The tissue samples were then homogenized
in 1.0 ml of phosphate buffered saline, pH 7.4, using a
Polytron PT1035 (Kinematica, Lucerne, Switzerland).
One hundred microliters of each sample was then added
to the scintillation vials with 4.9-ml scintillation solution
and stored for 2 days in the dark to allow any chemilu-
minescence to subside. The radioactivity was then quan-
tiﬁed on a scintillation counter (Beckman LS 6000 LL,
Beckman Instruments, Fullerton, CA), and content deter-
mined from control curves in which drug was added
directly to the homogenates made from mice not injected
with any drug.
Extraction of drug from plasma and tumor tissue
Non-polymer bound PTX and hydrophobic PTX metabo-
lites were extracted from 100-ll aliquots of plasma or
tissue homogenate by mixing 1.0-ml ethyl acetate for 1 h at
room temperature. The sample was then centrifuged at
2,5009g for 10 min, the organic phase was removed and
the aqueous phase re-extracted with two additional 1.0-ml
aliquots of ethyl acetate. The three organic extracts were
then combined, dried, and then resuspended in 100 llo f
50% acetonitrile. Total extractable drug was quantiﬁed by
scintillation counting as described above.
HPLC assay of extractable native PTX
The fraction of the total extractable [
3H] that was still in
the form of native PTX following injection of either
[
3H]PTX or PGG–[
3H]PTX was determined by separation
of native drug from metabolites by HPLC. A 100-ll aliquot
of either plasma or tissue homogenate was extracted with 5
vol of ethyl acetate and the organic phase was then
recovered, dried, and the residue redissolved in 95-llo f
50% acetonitrile and mixed with 5-ll non-radiolabeled
PTX at a concentration of 0.1 mg/ml. A total of 100 llo f
the reconstituted solution was injected onto a Beckman
HPLC equipped with an online scintillation detector. The
HPLC system consisted of a 150 9 4 mm Phenomenex
column, a UV/visible light detector set at 228 nm (System
Gold 168 Detector), and a ﬂow scintillation analyzer
(PerkinElmer Radiomatic 610 TR). The column was eluted
with a linear 20–95% acetonitrile gradient at a ﬂow rate of
0.3 ml/min for 30 min, a 30 min washout was allowed for
the system to return to initial conditions. The retention time
of native paclitaxel was 20 min, the offset time between
the UV and radioactive detectors was *0.2 min, the efﬁ-
ciency of [
3H] counting was 33%. The radioactivity
migrating with the peak of native PTX was quantiﬁed. A
standard curve was established for plasma and each type of
tissue homogenate separately by adding known amounts of
[
3H]PTX to 1 ml of plasma or tissue homogenates from
mice not injected with any radioactivity and the drug
content was expressed as counts per minute per gram of
tissue or milliliter plasma. The standard curves were linear
from 45 to 3,000 ng/ml and were run with each set of tissue
extracts. The lower limit of quantitation was 45 ng/ml.
Determination of drug excretion and elimination
To determine the routes of elimination of [
3H]PTX fol-
lowing injection of either [
3H]PTX or PGG–[
3H]PTX,
normal female nu/nu mice were injected with [
3H]-PTX (6
mice) or PGG–[
3H]PTX (6 mice) at a dose of 40 mg PTX
equivalents/kg body weight. The mice were placed in
metabolic cages, and urine and feces were collected during
the following intervals: 0–4, 4–8, 8–24, 24–48, 48–72, 72–
96, 96–120, 120–144, 144–168, 168–196, 196–210 and
210–240 h. The collected samples were analyzed for total
radioactivity.
Estimation of pharmacokinetic parameters
Pharmacokinetic analysis was based on non-compart-
mental methods using WinNolin version 5.2 (Pharsight
Corporation, San Francisco, CA, USA). The area under
the drug concentration–time curves was calculated from
mean tissue content values observed from the time of
drug injection to 340 h after administration using the
linear/log trapezoidal rule. The curves shown in the ﬁg-
ures represent mean values as a function of time and are
not ﬁtted to the data.
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All two-way comparisons were made with Student’s t test
assuming unequal variance of the samples. A P value of
\0.05 was considered signiﬁcant.
Results
PGG–PTX stability
The rate of release of PTX from the PGG polymer back-
bone was examined by incubating PGG–PTX at a con-
centration of 6 mg/ml in vitro in fresh human plasma at
37C. The free native PTX was then quantiﬁed by HPLC
analysis following extraction into ethyl acetate. Figure 2
shows that there was no detectable immediate release of
PTX. The rate of release was more rapid over the ﬁrst 6 h
and then slowed after the ﬁrst 10 h and was subsequently
quite constant till 144 h. A total of 6.1 ± 1.0 (SEM) % of
the PTX was released in 24 h.
Pharmacokinetics of total taxanes, extractable taxanes,
and native PTX in plasma
To determine the pharmacokinetic proﬁle of PGG–PTX
relative to that of PTX in plasma and tissues, female nu/nu
mice bearing subcutaneous NCI-H460 human lung cancer
xenografts were given IV bolus doses of either [
3H]PTX or
PGG–[
3H]PTX at a dose of 40-mg PTX equivalents/kg.
Samples of plasma, tumor, and the major organs were
collected at various time points till 340 h after the injection
and the levels of three different forms of the drugs were
determined by scintillation counting. The level of total
taxane was determined by measuring the radioactivity in
the entire sample which included PTX bound to plasma
proteins or the PGG polymer backbone, as well as native
drug and metabolites. When the plasma or tissue homog-
enates were extracted with ethyl acetate, the water-soluble
PGG–[
3H]PTX remained in the aqueous phase while native
PTX with any metabolites, referred to here as ‘extractable
taxanes’, were recovered in the organic phase. Since the
relative activities of the components in the ‘extractable
taxanes’ are unknown, native PTX was separated from its
metabolites in the ethyl acetate extract on an HPLC column
which permitted quantiﬁcation of the native form of PTX
present at each time point following injection of either
[
3H]PTX or PGG–[
3H]PTX [2, 10, 26, 27].
As shown in Fig. 3, and summarized in Table 1, there
were substantial differences in the plasma pharmacokinet-
ics of PTX and PGG–PTX. The total taxane Cmax was 8.5-
times higher in animals given PGG–PTX than in those
given PTX. The estimated terminal half-life values for total
taxanes were 293.6 h for PGG–PTX and 59.9 h for PTX.
As shown graphically in Fig. 3c, the AUC0–340 of total
taxanes in mice injected with PGG–PTX was 23.6-fold
greater than that for mice injected with PTX. Consistent
with the polymeric structure of PGG–PTX, its volume of
distribution was only 21%, and its plasma clearance was
only 4%, of that of PTX.
There were more modest differences in extractable
taxane and native PTX levels following injection of PTX or
PGG–PTX. The Cmax and AUC0–340 of extractable taxane
produced by injection of PGG–PTX were only 1.2 and 4.9-
fold, respectively, higher than that produced by injection of
PTX. Likewise, the Cmax and AUC of native PTX produced
by injection of PGG–PTX were only 1.5- and 4.0-fold,
respectively, higher than that produced by injection of
PTX. These results are consistent with the concept that
PTX is released from PGG–PTX quite slowly in plasma,
and that the larger AUC for extractable taxane and native
PTX following injection of PGG–PTX is largely due to its
more prolonged half-life.
Pharmacokinetics of total taxanes, extractable taxanes,
and native PTX in tumor
Figure 4 presents the curves of tumor content of each of the
three forms of the drugs as a function of time following
injection of either PGG–PTX or PTX, and the estimated
pharmacokinetic parameters are presented in Table 2.
Comparison of tumor to plasma for PGG–PTX
In contrast to the situation in plasma, following injection of
PGG–PTX, the peak tumor concentration of total taxane
was only 2.1-fold higher than that of extractable taxane and
4.3-fold higher than that of native PTX indicating that a
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Fig. 2 Release of PTX from PGG–PTX as a function of time during
incubation in fresh human plasma at 37C. Each point represents the
mean of three samples; vertical bars, SEM
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123larger fraction of the total drug present at the time of the
peak was in the form of native drug in the tumor tissue than
in plasma. The content of the extractable taxane and native
PTX initially declined more rapidly than the total taxane
level. As shown in Fig. 4c, the AUC0–340 for native PTX
over the time period measured was fully 20% of that of the
total taxane (compared to only 3.6% for plasma) and that
for extractable taxane was 32% of the total (compared to
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Fig. 3 Concentration of total
taxane, extractable taxane and
native PTX in plasma as a
function of time following
injection of PTX or PGG–PTX.
a Following injection of PTX
plotted over 0–340 h, b
following injection of PTX
plotted over just the ﬁrst 24 h, c
following injection of PGG–
PTX plotted over 0–340 h, d
following injection of PGG–
PTX plotted over just the ﬁrst
24 h, e the AUC0–340 values
following injection of PGG–
PTX relative to the following
injection of PTX. Filled square
total taxane, ﬁlled diamond
extractable taxane, ﬁlled
triangle native PTX. Each data
point is the mean of six samples
obtained from six mice at each
time point; vertical bars, SEM
Table 1 Estimated plasma pharmacokinetic parameters for total and extractable taxane and native PTX
Drug injected Half-live
(h)
Tmax
(h)
Cmax
(lg/ml)
Clast
(lg/ml)
AUClast
(h 9 lg/ml)
Vz
(ml/kg)
Clearance
(ml/h kg)
PTX
Total taxane 59.9 0.166 60.5 0.036 146.3 23,167.8 267.7
Extractable taxane 34.8 0.166 26.6 0.018 56.9 34,670.2 691.9
Native PTX 31.6 0.166 11.6 0.0014 31.4 57,967.4 1,273.4
PGG–PTX
Total taxane 296.2 0.5 517.1 0.085 3,454.4 4,896.7 11.5
Extractable taxane 253.1 0.166 31.9 0.065 279.4 48,204.1 132
Native PTX 68.1 0.166 18.3 0.0197 125.7 30,805.9 313.4
Tmax time after injection at which maximum concentration was detected; Cmax maximum concentration measured; Clast concentration at last time
point measured, 340 h; AUClast area under the concentration times time curve from 0 to 340 h; Vz estimated volume of distribution
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1238.1% for plasma). This result indicates that relatively more
of the PTX came off from the polymer backbone and/or
was metabolized to ethyl acetate-extractable forms during
the ﬁrst 340 h after PGG–PTX injection in tumor than in
plasma. Overall, the total exposure of the tumor to total
taxane was only 72% for plasma; however, exposure of the
tumor to extractable taxane was 2.9-fold higher than in
plasma and exposure to native PTX was 4.0-fold higher.
This result indicates that PGG–PTX delivered more
exposure to native PTX to the tumor than to the plasma,
indicative of its ability to concentrate in the tumor.
Comparison of tumor to plasma for PTX
In mice injected with PTX, the peak tumor concentration of
total taxane in the tumor was only 1.4-fold higher than that
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PTX in tumor as a function of
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Table 2 Estimated
pharmacokinetic parameters for
total and extractable taxane and
native PTX in tumor
MRT mean residence time
Drug injected Half-live
(h)
Tmax
(h)
Cmax
(lg/ml)
Clast
(lg/ml)
AUClast
(h 9 lg/ml)
CLobs
(ml/h kg)
MRT
(h)
PTX
Total taxane 51.5 2 8.3 0.029 322.5 123.2 56.9
Extractable taxane 40 2 6.1 0.019 139 285.2 32
Native PTX 70.9 2 5.5 0.04 143.7 269.6 67.3
PGG–PTX
Total taxane 97.4 4 17.5 2 2,496 14.6 140.5
Extractable taxane 59 24 8.5 0.19 802.7 48 82
Native PTX 51 24 4.1 0.12 498 78.8 92.9
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123of extractable taxane (compared to 2.3-fold higher for
plasma) and only 1.5-fold higher than that of native PTX
(compared to 5.2-fold higher in plasma). At the peak time,
66% fully of the total level was made up of native drug.
This suggests that, relative to native drug in plasma, native
PTX was concentrated into the tumor. The AUC0–340 for
native PTX over the time period measured was 45% of that
of the total taxane and that for extractable taxane was 43%
of the total, both values were higher than that observed in
plasma (21 and 39%, respectively). To summarize, the
exposure to native drug for the tumor was 14% greater than
that for the plasma (Figs. 3c, 4c). In contrast to the situa-
tion following injection of PGG–PTX, the decline in the
levels of extractable taxane and native PTX in the tumor
was only marginally more rapid than that of the total
taxane.
Drug levels produced by PTX versus PGG–PTX in tumor
As for the plasma pharmacokinetics, the behavior of the
two drugs was quite different with respect to accumulation
and washout from the tumor tissue. The key differences
were that, while the peak concentration of total taxane
attained in the tumor (Cmax) after injection of PGG–PTX
was 2.1-fold higher than after injection of PTX, the total
taxane level in the tumor following injection of PGG–PTX
continued to increase for a 1.9-fold longer period of time
following injection of PTX. The time of maximal accu-
mulation for PGG–PTX was 4 h whereas it was just 2 h for
PTX. In addition, the washout of PGG–PTX was slower as
reﬂected by the 1.9-fold longer estimated terminal half-life.
The combination of a higher Cmax, a more prolonged tumor
accumulation phase, and slower washout resulted in an
AUC0–340 for total taxane in the tumor being 7.7-fold
greater for PGG–PTX than for PTX (Figs. 3c, 4c).
The Cmax of extractable taxanes in the tumor was 1.4-
fold higher following injection of PGG–PTX than PTX but
the main difference was that the extractable taxane gen-
erated by PGG–PTX continued to accumulate in the tumor
for a much longer period of time (12-fold) such that the
time of maximal accumulation was 24 h versus just 2 h
following injection of PTX. The combination of a higher
Cmax, more prolonged tumor accumulation phase, and
slower washout resulted in a total exposure for the tumor
being 5.7-fold greater for extractable taxanes following
injection of PGG–PTX than of PTX.
Assuming that the native drug is the most important with
respect to tumor cell kill, a comparison of the AUC0–340 for
native drug in mice injected with PGG–PTX to that in mice
injected with PTX is of particular interest. The Cmax pro-
duced by the former was 1.4-fold higher than that produced
by the latter, but there was a large difference in the period
of accumulation (12-fold) and washout (3.4-fold) in favor
of PGG–PTX. This resulted in an AUC0–340 for native drug
that was 3.5-fold higher following injection of PGG–PTX.
Thus, PGG–PTX was substantially more effective at
delivering the most important form of the drug to the tumor
than PTX.
Pharmacokinetics of total taxanes in major organs
Whereas, all three forms of the drugs were measured in the
plasma and tumor, only total taxanes were measured in the
major organs. The drug content per gram wet weight is
shown for liver, lung, kidney, spleen, and skeletal muscle
as a function of time in Fig. 5. The estimated pharmaco-
kinetic parameters are presented in Table 3. The data for
plasma and tumor are included in Table 3 for ease of
comparison, and Fig. 6 presents a summary of the Cmax and
AUC data in graphic form.
In all the organs tested, decay in the content of total
taxane following injection of PGG–PTX was much slower
than PTX. PGG–PTX produced Cmax values of total taxane
that were quite similar in the liver, lungs, and spleen
whereas they were more variable following injection of
PTX with a particularly high level in the lung. Given the
particulate nature of the PGG–PTX, one might have
expected a higher Cmax following injection of PGG–PTX in
both the liver and spleen; however, while they were 2.7-
fold higher in the spleen, the liver levels were similar. The
levels in the liver were also of interest because, the total
taxane content dropped rapidly between 0.166 and 48 h
after injection of PTX; following injection of PGG–PTX,
the level continued to increase over this interval eventually
reaching a peak concentration equal to 90% of that attained
by PTX. Once having reached its peak level, the washout
of total taxane generated by PGG–PTX was very slow; the
clearance from the liver after injection of PGG–PTX was
only 1.5% of that after administration of PTX. The esti-
mated terminal half-life of total taxane washout from the
liver was 9.5-fold slower for PGG–PTX than for PTX
resulting in 33.4-fold AUC0–340 for PGG–PTX as shown in
Fig. 6. The drugs also exhibited quite different behavior in
the lungs. The Cmax produced by PGG–PTX was only 60%
of that produced by PTX; however, the AUC produced by
PGG–PTX was 34.5-fold higher than that produced by
injection of PTX and the estimated terminal half-life of
total taxane washout from the lung was 3.4-fold slower for
PGG–PTX than PTX. The clearance of total taxane from
the lungs following injection of PGG–PTX was only 2.5%
of that after injection of PTX.
The pattern of accumulation and washout of total taxane
in the kidneys resembled that of the liver. Whereas, the
level of total taxane following injection of PTX started
falling right away, after administration of PGG–PTX, it
continued to accumulate over the ﬁrst 1 h and thereafter the
Cancer Chemother Pharmacol (2010) 65:515–526 521
123level remained quite stable, such that the concentration at
the last time point measured was the same as the Cmax. The
peak kidney level associated with PGG–PTX was only
90% of that produced by PTX but the total exposure was
30.9-fold higher. The very slow washout of PGG–PTX
from the kidney precluded estimation of the terminal half-
life or clearance.
The pattern of accumulation and washout of total taxane
produced by PGG–PTX and PTX in the spleen again
resembled that in other organs with the exception that the
Cmax after injection of PGG–PTX exceeded that produced
with PTX by 2.7-fold. Whereas, the level declined rapidly
after injection of PTX, it continued to accumulate over the
ﬁrst 4 h after administration of PGG–PTX and thereafter
remained quite stable. The total exposure was 72.8-fold
higher for PGG–PTX and PTX. The very slow washout
from the spleen after injection of PGG–PTX precluded
estimation of the terminal half-life or clearance.
Muscle was the only tissue in which the pattern of
accumulation and washout differed signiﬁcantly from that
in liver, lungs, kidneys, and spleen. In muscle, total taxane
after injection of PGG–PTX did not show a period of
accumulation as was seen in all the other tissues; instead,
levels followed plasma levels, progressively declining after
completion of the injection. In addition, the total taxane
and AUC ratio of 2.7 was substantially smaller than that
observed for the other tissues suggesting that PGG–PTX
nanoparticles have a lower afﬁnity for muscle than the
other tissues tested.
Excretion of total taxanes derived from PTX
and PGG–PTX in the urine and feces
Groups of six mice injected with 40-mg PTX equivalents/
kg of either [
3H]PTX or PGG–[
3H]PTX were maintained in
metabolic cages, and urine and feces were quantitatively
recovered over a period of 240 h. The total taxane level
was measured by scintillation counting with appropriate
controls for possible quenching. As shown in Fig. 7, the
two drugs showed quite different patterns of urinary
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123excretion. The urinary excretion of total taxanes following
injection of PTX was more rapid than that after injection of
PGG–PTX over the ﬁrst 24 h. Following injection of PGG–
PTX, 13.3% of the PTX dose administered was excreted in
urine within the ﬁrst 48 h and 16.9% over the entire 240 h.
In contrast, following injection of PTX, 23.4% was
excreted in the urine within the ﬁrst 48 h and 24.7% was
excreted in 240 h. Thus, essentially all the radioactivity
excretable in the urine following the injection of uncon-
jugated PTX appeared in the ﬁrst 24 h and very little
thereafter. In contrast, while most of the radioactivity
excretable in the urine following injection of PGG–PTX
came out in the ﬁrst 48 h, an additional 3% appeared in the
urine at later time points.
A substantial fraction of the administered dose was
recovered in feces for both drugs. The fecal excretion of
total taxane following injection of PTX was substantially
more rapid than that of PGG–PTX over the ﬁrst 24 h.
Following injection of PGG–PTX, 36.5% of the injected
dose was excreted in the feces within the ﬁrst 48 h and
45.3% over the entire 240-h. In contrast, following injec-
tion of PTX, 72.3% was excreted in the feces within the
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Table 3 Estimated
pharmacokinetic parameters for
total taxanes in the liver, lungs,
kidneys, spleen, and muscle
from mice injected with either
PTX or PGG–PTX
NE could not be estimated
a Ratio of PGG–PTA to PTX
Organ Drug Half-life (h) Tmax h Cmax
(lg/g or ml)
Cmax ratio
a AUC0–340 h
(lg h/ml)
AUC ratio
a
Liver PGG–PTX 310.7 48.0 230.7 0.9 54,332.6 33.4
PTX 32.4 0.50 255.8 1,622.9
Lung PGG–PTX 102.9 0.16 205.5 0.6 10,107.9 34.5
PTX 29.4 0.16 331.8 292.2
Kidney PGG–PTX NE 1.00 131.4 0.9 14,418.2 30.9
PTX 39 0.16 134.1 292.2
Spleen PGG–PTX NE 4.00 223.2 2.7 39,080 72.8
PTX 14.4 1.00 80.2 536.6
Muscle PGG–PTX 109.1 0.16 4.9 0.2 311.5 2.7
PTX 57.5 0.50 24.8 112.2
Tumor PGG–PTX 97.4 4.00 17.5 2.1 2,496.1 7.7
PTX 51.5 2.00 8.3 322.5
Plasma PGG–PTX 296.2 0.16 517.1 8.5 3,454.3 23.6
PTX 59.9 0.16 60.5 146.3
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123ﬁrst 48 h and 95.2% was excreted over the full 240 h
sampling period. Thus, the majority of the radioactivity
excreted in the feces following injection of PTX came out
in the ﬁrst 48 h whereas most of the radioactivity excreted
in the feces following injection of PGG–PTX came out in
the ﬁrst 48 h, an additional 23% appeared in the feces at
later time points.
Discussion
Polymer–drug conjugates have been investigated as carriers
for anticancer drugs in an attempt to direct active agents to
tumors in vivo and to reduce toxic effects to normal tissues
[4, 7, 10, 15]. The increased antitumor efﬁcacy of polymeric
drugs has been shown to be largely attributable to the
enhanced permeability and retention (EPR) effect of mac-
romolecules [15]. At present, a few polymer–drug conju-
gates have reached the stage of clinical application. A
hydroxypropyl methacrylamide copolymer (HPMA)–doxo-
rubicin conjugate (PK1) was shown to have antitumor
activity and decreased toxicity relative to free doxorubicin in
patients with refractory tumors in phase I clinical studies
[30] but was not developed further. HPMA–cisplatin and
HPMA–DACH platinum conjugates have demonstrated
substantial activity in preclinical studies [13, 20]a n d
favorable pharmacokinetics in initial phase 1 clinical trials
[19]. Paclitaxel poliglumex, a formulation in which paclit-
axel is linked to a PGA polymer, has activity in preclinical
studies and early clinical trials but has yet to demonstrate a
superior therapeutic index in randomized phase III trials.
PGG–PTX differs signiﬁcantly from paclitaxel poliglu-
mex in two important ways. First, while the molecular
weight of the polymer in paclitaxel poliglumex is 35 kDa
by viscosity and *20 kDa by multi-angle light scattering,
the addition of a glutamine acid to each glutamyl in the 70-
kDa polymer backbone of PGG increases its molecular
weight to the range of *52 kDa by multi-angle light
scattering. Second, when PGG is loaded to 35% by weight
with PTX, it forms micelles with a median diameter of
20 nm in aqueous environments and thus can be expected
to behave more as a nanoparticle than as a ﬂexible polymer
as it traverses the circulation and tumor extracellular
compartments. PGG–PTX was designed to deliver more
PTX to the tumor than to other dose-limiting tissues. In
order to achieved this, a formulation was needed that
would release little of its PTX cargo in the systemic cir-
culation, but would release essentially all of it once in the
tumor. Although the PTX is linked to the PGG backbone
via an ester linkage, the rate of release of PTX from the
polymer in human plasma was quite slow and only 6.1%
was released within 24 h. Although the rate of release of
PTX from the polymer could not be measured directly in
the tumor, the goal of increasing delivery of PTX to the
tumor was clearly achieved as documented by increased
total taxane, extractable taxane, and native PTX exposures
for the tumor following injection of PGG–PTX compared
to administration of an equal amount of unconjugated PTX.
The AUC ratios were 7.7 for total taxane, 5.7 for extract-
able taxane, and 3.5 for native PTX. These increases were
the result of both modestly higher Cmax values but sub-
stantially more prolonged periods of drug accumulation in
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123the tumor and slower washout of all three forms of the drug
following administration of PGG–PTX compared to PTX.
One of the questions of interest with regard to PGG–
PTX is whether the increase in tumor exposure is simply
the result of an increase in plasma AUC, or whether the
PGG–PTX micelles are truly able to accumulate in the
tumor. The observation that the tumor AUC for all three
forms of the drug was much higher than the plasma AUC
indicates that a large degree of targeting was in fact
attained even when taking into consideration that the units
for the plasma are lg h/ml whereas those for the tumor are
lg h/g. The ratio was 17 for total taxane, 14 for extractable
taxane, and 16 for native PTX.
As shown in Fig. 5, PGG–PTX delivered a lot more
total taxane to the liver, lungs, kidneys, and spleen than to
the tumor. However, it is important to note that the clinical
efﬁcacy of PTX is based not on the fact that most drug gets
to the tumor than to other tissues, but that more of it gets
into the tumor than to those tissues that limit its dose. None
of these organs are dose-limiting for PTX. Despite
increasing exposure for the liver, lungs, spleen, and kid-
neys by large amounts, in mice PGG–PTX is substantially
less toxic than PTX. In nu/nu mice, the maximum tolerated
dose of a single injection of PGG–PTX is *400 mg/kg
whereas the maximum tolerated dose of a single IV
injection of PTX is 100 mg/kg. Thus, the expectation is
that, when injected at equitoxic doses instead of equimolar
doses, the magnitude of the increase in the amount of drug
delivered to the tumor will be even greater.
Consistent with studies of paclitaxel poliglumex [25],
linkage of PTX to the PGG backbone markedly altered its
urinary and fecal excretion. Whereas, excretion of taxanes
derived from injection of unconjugated PTX was largely
complete in the urine in 24 h, and in the feces by 120 h,
and a total of 95.7% of the injected dose had been excreted
by both routes in 240 h the excretion of taxanes after the
injection of PGG–PTX continued throughout the entire
sampling period and only 49.8% of the total dose had been
excreted by 240 h. Thus, linkage of PTX to PGG markedly
reduced its access to both the urinary and biliary excretion
pathways and prolonged its residence time. It is important
to note that only total radioactivity was measured in this
experiment and it remains unknown what fraction of the
radioactivity appearing in either the urine or feces is
unchanged PTX or PGG–PTX and how much is metabo-
lites. The data from these experiments are nevertheless
consistent with the previous ﬁndings that hepatic metabo-
lism and biliary excretion are principal mechanisms of
PTX elimination [1, 29]. PGG–PTX appears to have less
relative access to hepatic metabolism and therefore has a
lower fecal excretion. The data from this experiment are
consistent with the concept that PTX is not released rapidly
from the polymer backbone following IV injection. If the
PTX had been rapidly released, one would have expected
to observe less of a difference in the rate of appearance of
radioactivity in the urine and feces compared to unconju-
gated PTX.
In summary, this study showed that PGG–PTX deliv-
ered substantially more of all three forms of PTX to the
tumor than did an equivalent PTX dose of 40 mg/kg.
Furthermore, the native PTX was present in tumor tissues
for up to 340 h after injection of PGG–PTX. The enhanced
tumor uptake of PGG–PTX and prolonged release of free
PTX within the tumor is consistent with the superior
antitumor activity of PGG–PTX observed in preclinical
studies.
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